Macro Strategy - In October, industrial enterprise profits showed a significant decline, with a year-on-year drop from 21.60% in September to -5.5% in October, leading to a cumulative year-on-year growth rate decrease from 3.20% to 1.90% [2] - The A-share market experienced a rebound from November 24 to November 28, with major indices such as the Shanghai Composite Index rising by 1.40% and the ChiNext Index increasing by 4.54% [3][4] - The rebound in A-shares was attributed to a reversal in the market's previous downward momentum, driven by a shift in expectations regarding the Federal Reserve's interest rate decisions and a recovery in the technology sector [3][4] Industry and Company Analysis Traditional Chinese Medicine Industry - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 1.29% last week, the smallest among secondary sub-sectors in the pharmaceutical industry [9] - The price index for TCM materials showed a slight increase of 0.4%, indicating a recovery in market conditions and improved investor sentiment [12] - Multiple regions have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive market structure [13] Investment Recommendations - The report maintains an "overweight" rating for the TCM industry, suggesting three main investment themes: 1. Price governance, focusing on companies with strong R&D capabilities and unique products that can benefit from price reductions [15] 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population, favoring leading TCM brands [16] 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [16] - Recommended stocks include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on companies with strong R&D capabilities and unique products [16]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 on December 23, 2025 [2][5] - The meeting will utilize a combination of on-site and online voting methods, with specific time slots for voting [3][6] - The company aims to enhance participation from small and medium investors by providing reminder services for the meeting [3][4] Group 2 - The company plans to provide a guarantee of 600 million RMB for its wholly-owned subsidiaries within a comprehensive credit limit for 2026 [20][21] - As of the announcement date, the actual guarantee balance provided to subsidiaries is 190 million RMB [21][26] - The company intends to apply for a total credit limit of up to 800 million RMB from various financial institutions [21][25] Group 3 - The company has decided to postpone the expected usable status date for two fundraising investment projects from November 30, 2025, to June 30, 2026 [29][36] - The postponement does not alter the total investment amount or construction scale of the projects [29][37] - The company emphasizes that the delay is a cautious decision based on market conditions and will not significantly impact its normal operations [37][39] Group 4 - The company has revised its remuneration management system for directors and senior management to align with current regulations and improve internal governance [42] - The revised system was approved during the sixth meeting of the fifth board of directors [42][41] Group 5 - The company plans to use up to 250 million RMB of temporarily idle fundraising and up to 1 billion RMB of idle self-owned funds for cash management in 2026 [55][56] - The investment will focus on low-risk financial products such as structured deposits and large certificates of deposit [58][64] - The decision to manage idle funds aims to enhance capital efficiency without affecting ongoing projects or normal operations [70][71]

证券日报网讯11月28日晚间，寿仙谷（603896）发布公告称，公司对外担保不存在逾期情形。 ...

Group 1 - The core point of the article is that Shouxiangu (SH 603896) held its sixth meeting of the fifth board of directors on November 28, 2025, to discuss the revision of the "Compensation Management System for Directors and Senior Management" [1] - For the first half of 2025, Shouxiangu's revenue composition was as follows: manufacturing accounted for 95.69%, other businesses accounted for 2.67%, and additional business activities accounted for 1.63% [1] - As of the time of reporting, Shouxiangu's market capitalization was 4 billion yuan [1]

国信证券股份有限公司 关于浙江寿仙谷医药股份有限公司 2026 年度使用部分 暂时闲置募集资金及自有资金进行现金管理的核查意见 国信证券股份有限公司（以下简称"国信证券"）作为浙江寿仙谷医药股份 有限公司（以下简称"寿仙谷"或"公司"）公开发行可转换公司债券并上市的 保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规 则》《上海证券交易所股票上市规则（2025 年 4 月修订）》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》等相关法律法规和规范性文件的要求， 经审慎核查，就寿仙谷拟使用部分暂时闲置募集资金及自有资金进行现金管理的 事项，发表专项核查意见如下： 一、募集资金基本情况 （一）2020 年公开发行可转换公司债券募集资金 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准浙江寿 仙谷医药股份有限公司公开发行可转换公司债券的批复》（证监许可[2020] 658 号） 核准，公司已公开发行总额为人民币 36,000 万元可转换公司债券，每张面值 100 元人民币，共 3,600,000 张，期限为 6 年。扣除公司为本次可转换公司债券所支 付的发行费用后，实际 ...

国信证券股份有限公司 关于浙江寿仙谷医药股份有限公司 2026 年度使用部分 暂时闲置募集资金及自有资金进行现金管理的核查意见 国信证券股份有限公司（以下简称"国信证券"）作为浙江寿仙谷医药股份 有限公司（以下简称"寿仙谷"或"公司"）公开发行可转换公司债券并上市的 保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规 则》《上海证券交易所股票上市规则（2025 年 4 月修订）》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》等相关法律法规和规范性文件的要求， 经审慎核查，就寿仙谷拟使用部分暂时闲置募集资金及自有资金进行现金管理的 事项，发表专项核查意见如下： 一、募集资金基本情况 （一）2020 年公开发行可转换公司债券募集资金 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准浙江寿 仙谷医药股份有限公司公开发行可转换公司债券的批复》（证监许可[2020] 658 号） 核准，公司已公开发行总额为人民币 36,000 万元可转换公司债券，每张面值 100 元人民币，共 3,600,000 张，期限为 6 年。扣除公司为本次可转换公司债券所支 付的发行费用后，实际 ...

经中国证监会《关于核准浙江寿仙谷医药股份有限公司公开发行可转换公司 债券的批复》（证监许可[2020] 658 号）核准，公司已公开发行总额为人民币 36,000 万元可转换公司债券，每张面值 100 元人民币，共 3,600,000 张，期限为 6 年。 扣除公司为本次可转换公司债券所支付的发行费用后，实际募集资金净额为 349,155,660.38 元。上述募集资金已于 2020 年 6 月 15 日全部到位并存放于募集 资金专户管理，立信会计师事务所（特殊普通合伙）已就募集资金到账事项进行 关于浙江寿仙谷医药股份有限公司 部分募集资金投资项目延期的核查意见 国信证券股份有限公司（以下简称"国信证券"或"保荐机构"）作为浙江 寿仙谷医药股份有限公司（以下简称"寿仙谷"或"公司"）公开发行可转换公 司债券并上市的保荐机构，根据中国证券监督管理委员会《证券发行上市保荐业 务管理办法》《上海证券交易所股票上市规则（2025 年 4 月修订）》《上市公司募 集资金监管规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关规定， 对寿 ...

浙江寿仙谷医药股份有限公司 董事及高级管理人员薪酬管理制度 第一章 总则 第一条 为进一步完善激励与约束机制，充分调动和发挥董事和高级管理人 员的积极性和创造性，持续提升公司经营业绩，确保公司发展战略目标和年度经 营指标的实现，根据《中华人民共和国公司法》（以下简称"《公司法》"）等有关 法律、法规和《浙江寿仙谷医药股份有限公司章程》（以下简称"《公司章程》"） 的规定，结合公司经营实际情况，制定本制度。 第二条 本制度适用于通过公司股东会选举的董事、由职工代表大会选举的 职工董事以及董事会聘任的高级管理人员。 第三条 公司董事和高级管理人员薪酬管理遵循以下原则： 二〇二五年十一月（修订） | | | 第四条 董事和高级管理人员的绩效评价由董事会下设的薪酬与考核委员会 负责组织，公司可以委托第三方开展绩效评价。 独立董事的履职评价采取自我评价、相互评价等方式进行。 第五条 董事会应当向股东会报告董事履行职责的情况、绩效评价结果及其 薪酬情况，并由公司予以披露。 第二章 薪酬结构与确定 第六条 公司董事的薪酬构成： （一）公司对于独立董事发放董事津贴，津贴数额与独立董事承担的职责相 适应，具体发放标准由薪酬与考 ...

| | | 修订后的《董事及高级管理人员薪酬管理制度》详见公司同日在上海证券交 易所网站（www.sse.com.cn）披露的相关制度全文。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江寿仙谷医药股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日召 开第五届董事会第六次会议，审议通过了《关于修订<董事及高级管理人员薪酬 管理制度>的议案》，拟对现行《董事及高级管理人员薪酬管理制度》进行修订。 具体内容公告如下： 为进一步促进公司规范运作，建立健全内部治理机制，根据《公司法》、《上 市公司章程指引》、《上市公司治理准则》、《上市公司股东会规则》、《上海证券交 易所股票上市规则》等相关法律、法规、规范性文件的最新规定，结合公司实际 情况修订了《董事及高级管理人员薪酬管理制度》，具体情况如下： | 序号 | 制度名称 | 类型 | 是否提交股东 | | --- | --- | --- | --- | | | | | 会审议 | | 1 | 《董事及高级管理人员薪酬管理制度》 | 修订 | 是 | ...